Edition:
United States

‍Moody's says biosimilars market adoption faces hurdles but development continues apace​


Thursday, 28 Sep 2017 11:53am EDT 

Sept 28 (Reuters) - Moody's::‍Moody's says biosimilars market adoption faces hurdles but development continues apace​.Moody's says slow launch of Pfizer's inflectra illustrates hurdles that biosimilar manufacturers face in gaining significant traction in the U.S.‍​.Moody's says potential changes to U.S. Medicare reimbursement could further encourage biosimilar adoption‍​.‍Moody's says among biggest reasons for biosimilars' slow adoption in U.S. is medicare reimburses providers at higher rates for innovator product use.‍Moody's says Medicare reimburses providers at lower rates for switching to the biosimilar from innovator product.‍Moody's says "biosimilar developers still have lots of room for growth, and we expect a number of new approvals over the next 12 to 18 months". 

Company Quote

35.37
-0.19 -0.53%
17 Nov 2017